A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Condition(s):Locally Advanced Head and Neck Squamous Cell CarcinomaLast Updated:February 29, 2024Recruiting